Gilead Sciences

Gilead Sciences
Coolcaesar · CC BY 4.0 · source
Name	Gilead Sciences
Type	Public
Founded	1987
Founder	Michael L. Riordan
Headquarters	Foster City, California, United States
Key people	Daniel O'Day, Jeremy Levin, John C. Martin
Industry	Biopharmaceuticals
Products	Antiretrovirals, Hepatitis C therapies, Oncology agents, COVID-19 antivirals
Revenue	See Financial Performance
Num employees	~14,000 (varies)

Gilead Sciences is a biopharmaceutical corporation founded in 1987 and headquartered in Foster City, California. The company is known for developing antiviral drugs, notably treatments for Human immunodeficiency virus (HIV/AIDS), Hepatitis C, and viral diseases including agents used during the COVID-19 pandemic. Gilead has engaged in mergers, acquisitions, and licensing that intersect with organizations such as Roche, Pharmasset, and Kite Pharma.

History

Gilead was founded in 1987 by Michael L. Riordan with early scientific leadership involving researchers affiliated with institutions such as Stanford University, University of California, San Francisco, and collaborations with corporations like Amgen and GlaxoSmithKline. In the 1990s the firm pursued antiviral research that led to partnerships with Merck & Co., AbbVie, and licensing arrangements invoking patents related to nucleoside analogs developed in laboratories connected to Columbia University and Emory University. The 2000s saw expansion through acquisitions including businesses tied to technologies from Triangle Pharmaceuticals and collaborations with Bristol-Myers Squibb. A landmark moment came with the acquisition of Pharmasset in 2011, which brought the hepatitis C direct-acting antiviral sofosbuvir into Gilead’s portfolio, later marketed amid regulatory interactions with agencies such as the U.S. Food and Drug Administration and reimbursement negotiations involving bodies like NHS England. Strategic moves included the 2017 acquisition of Kite Pharma to enter cell therapy and earlier licensing deals with GSK and Fujifilm affiliates. Corporate milestones involve leadership tenures by executives such as John C. Martin and a CEO succession that included figures with ties to firms like Roche and Novartis.

Products and Research Pipeline

Gilead’s marketed products include antiretroviral therapies originating from collaborations and scientific work connected to Yale University and clinical networks such as the ACTG (AIDS Clinical Trials Group); notable regimens include combination treatments analogous to medicines developed at ViiV Healthcare and Merck Sharp & Dohme facilities. The hepatitis C portfolio, developed from assets acquired from Pharmasset, competed with therapies from InterMune and Boehringer Ingelheim. Oncology and cell therapy efforts stem from the acquisition of Kite Pharma and relate to the broader CAR-T field alongside players such as Novartis and Juno Therapeutics. During the COVID-19 pandemic, Gilead developed antiviral remdesivir, researched in coordination with institutions like NIH, University of Alabama at Birmingham, and manufacturing partners including Thermo Fisher Scientific affiliates. The pipeline has included investigational agents for Influenza and broader antiviral classes studied in collaboration with groups such as Wellcome Trust-funded research and academic centers like Massachusetts General Hospital. Preclinical and clinical programs have involved partnerships with biotech firms such as Galapagos NV, Sangamo Therapeutics, and academic spinouts from MIT and Harvard Medical School laboratories.

Corporate Governance and Leadership

Board composition and executive management have featured leaders with prior roles at corporations and institutions including Roche, Bristol-Myers Squibb, Pfizer, and academic appointments at Stanford University School of Medicine and UCSF. Corporate governance practices interact with regulators such as the SEC (U.S. Securities and Exchange Commission) and disclosure norms influenced by precedents involving firms like Enron and Theranos in terms of investor scrutiny. Notable board members and executives have included individuals with backgrounds at Johnson & Johnson, Eli Lilly and Company, and venture capital firms tied to KPCB (Kleiner Perkins), and they maintain relationships with global health organizations such as the World Health Organization and philanthropic entities exemplified by the Bill & Melinda Gates Foundation.

Financial Performance and Markets

Gilead’s financial results have been reported in the context of quarterly earnings calls and filings with the SEC (U.S. Securities and Exchange Commission), evaluated by market analysts at firms like Goldman Sachs, JPMorgan Chase, and Morgan Stanley. Revenues surged following launches of hepatitis C products in competition with offerings from AbbVie and Roche, with market dynamics influenced by pricing debates involving national payers including Medicare and institutions like NHS England. The company has engaged in secondary offerings, debt financing, and acquisition financing comparable to transactions by Amgen and Celgene; investors track metrics alongside indices such as the NASDAQ Composite and the S&P 500. Stock performance has been compared to peers including Biogen, Regeneron Pharmaceuticals, and Vertex Pharmaceuticals with market capitalization shifts reported during periods of pipeline announcements and regulatory decisions by agencies such as the European Medicines Agency.

Controversies and Legal Issues

Gilead has faced patent litigation and pricing controversies analogous to disputes involving Martin Shkreli-era controversies and cases seen with Turing Pharmaceuticals and Insys Therapeutics. High-profile legal matters included intellectual property suits against and by companies such as Merck & Co., Bristol-Myers Squibb, and generic manufacturers like Teva Pharmaceutical Industries and Mylan. Pricing and access debates involved governments and NGOs including Doctors Without Borders (Médecins Sans Frontières), procurement negotiations with UNAIDS, and compulsory licensing discussions reminiscent of disputes under frameworks involving the World Trade Organization and the TRIPS Agreement. Investigations and settlements have intersected with agencies such as the U.S. Department of Justice and state attorneys general, echoing enforcement actions seen with GlaxoSmithKline and Purdue Pharma in other contexts.

Corporate Social Responsibility and Global Health Initiatives

Gilead has participated in access programs and voluntary licensing strategies with global partners including Medicines Patent Pool, civil society organizations like Oxfam, and manufacturers across India and Brazil. Public-private collaborations have included work with the World Health Organization, UNICEF, and national public health agencies such as CDC and Public Health England to expand treatment access modeled after programs by The Global Fund. Philanthropic contributions and capacity-building initiatives have been aligned with foundations such as the Bill & Melinda Gates Foundation and partnerships with academic centers including Johns Hopkins University and Imperial College London for research training and implementation science projects. Efforts on pandemic preparedness echo multilateral initiatives alongside entities like CEPI and coordination with distribution mechanisms similar to COVAX.

Category:Biopharmaceutical companies Category:Companies based in California Category:Pharmaceutical companies established in 1987